Journal Article
. 2006 Apr; 295(14):1658-67.
doi: 10.1001/jama.295.14.1658.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A Berry 1 Constance Cirrincione  I Craig Henderson  Marc L Citron  Daniel R Budman  Lori J Goldstein  Silvana Martino  Edith A Perez  Hyman B Muss  Larry Norton  Clifford Hudis  Eric P Winer  
Affiliations
  • PMID: 16609087
  •     28 References
  •     205 citations

Abstract

Context: Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy.

Objective: To compare differences in benefits from adjuvant chemotherapy achieved by patients with ER-negative vs ER-positive tumors.

Design, Setting, And Patients: Trial data from the Cancer and Leukemia Group B and US Breast Cancer Intergroup analyzed; patient outcomes by ER status compared using hazards over time and multivariate models. Randomized trials comparing (1): 3 regimens of cyclophosphamide, doxorubicin, and fluorouracil (January 1985 to April 1991); (2) 3 doses of doxorubicin concurrent with cyclophosphamide, with or without subsequent paclitaxel (May 1994 to April 1997); (3) sequential doxorubicin, paclitaxel, and cyclophosphamide with concurrent doxorubicin and cyclophosphamide followed by paclitaxel, and also 3-week vs 2-week cycles (September 1997 to March 1999). A total of 6644 node-positive breast cancer patients received adjuvant treatment.

Main Outcome Measures: Disease-free and overall survival.

Results: For ER-negative tumors, chemotherapy improvements reduced the relative risk of recurrence by 21%, 25%, and 23% in the 3 studies, respectively, and 55% comparing the lowest dose in the first study with biweekly cycles in the third study. Corresponding relative risk reductions for ER-positive tumors treated with tamoxifen were 9%, 12%, and 8% in the 3 studies, and 26% overall. The overall mortality rate reductions associated with chemotherapy improvements were 55% and 23% among ER-negative and ER-positive patients, respectively. All individual ER-negative comparisons and no ER-positive comparisons were statistically significant. Absolute benefits due to chemotherapy were greater for patients with ER-negative compared with ER-positive tumors: 22.8% more ER-negative patients survived to 5 years disease-free if receiving chemotherapy vs 7.0% for ER-positive patients; corresponding improvements for overall survival were 16.7% vs 4.0%.

Conclusion: Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Subgroup analyses.
D A Berry.
Biometrics, 1990 Dec 01; 46(4). PMID: 2085637
Effect of screening and adjuvant therapy on mortality from breast cancer.
Donald A Berry, Kathleen A Cronin, +8 authors, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.
N Engl J Med, 2005 Oct 28; 353(17). PMID: 16251534
Highly Cited.
Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
Heikki Joensuu, Tiina Lehtimäki, +7 authors, Johan Lundin.
JAMA, 2004 Sep 02; 292(9). PMID: 15339900
Efficacy and safety of trastuzumab.
Robin L Jones, Ian E Smith.
Expert Opin Drug Saf, 2004 Jul 23; 3(4). PMID: 15268649
Review.
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
R Charles Coombes, Emma Hall, +24 authors, Intergroup Exemestane Study.
N Engl J Med, 2004 Mar 12; 350(11). PMID: 15014181
Highly Cited.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
Early Breast Cancer Trialists' Collaborative Group.
N Engl J Med, 1988 Dec 29; 319(26). PMID: 3205265
Highly Cited.
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Marco Colleoni, Giuseppe Viale, +13 authors, Aron Goldhirsch.
Clin Cancer Res, 2004 Oct 12; 10(19). PMID: 15475452
Trastuzumab in breast cancer.
Leisha A Emens, Nancy E Davidson.
Oncology (Williston Park), 2004 Oct 09; 18(9). PMID: 15471197
Review.
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
Yu Shen, Ying Yang, +3 authors, Donald A Berry.
J Natl Cancer Inst, 2005 Aug 18; 97(16). PMID: 16106024
Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
G Bruce Mann, Vanessa D Fahey, Frank Feleppa, Malcolm R Buchanan.
J Clin Oncol, 2005 Jul 30; 23(22). PMID: 16051956
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
S Rueckert, I Ruehl, +2 authors, M Untch.
Expert Opin Biol Ther, 2005 Jun 15; 5(6). PMID: 15952915
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Orphan comparisons and indirect meta-analysis: a case study on antidepressant efficacy in dysthymia comparing tricyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors by using general linear models.
Javier Ballesteros.
J Clin Psychopharmacol, 2005 Mar 02; 25(2). PMID: 15738743
Subgroup analysis and other (mis)uses of baseline data in clinical trials.
S F Assmann, S J Pocock, L E Enos, L E Kasten.
Lancet, 2000 Apr 01; 355(9209). PMID: 10744093
Highly Cited.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
M Baum, A U Budzar, +5 authors, ATAC Trialists' Group.
Lancet, 2002 Jul 02; 359(9324). PMID: 12090977
Highly Cited.
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG).
J Natl Cancer Inst, 2002 Jul 18; 94(14). PMID: 12122096
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
I Craig Henderson, Donald A Berry, +16 authors, Larry Norton.
J Clin Oncol, 2003 Mar 15; 21(6). PMID: 12637460
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
Donald A Berry, Scott M Berry, John McKellar, Thomas A Pearson.
Am Heart J, 2003 Jun 11; 145(6). PMID: 12796760
Review.
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Paul E Goss, James N Ingle, +15 authors, Joseph L Pater.
N Engl J Med, 2003 Oct 11; 349(19). PMID: 14551341
Highly Cited.
Ongoing adjuvant trials with trastuzumab in breast cancer.
Antoinette R Tan, Sandra M Swain.
Semin Oncol, 2003 Nov 13; 30(5 Suppl 16). PMID: 14613027
Review.
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
H B Muss, A D Thor, +7 authors, M Barcos.
N Engl J Med, 1994 May 05; 330(18). PMID: 7908410
Highly Cited.
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, D C Tormey, R Gray.
J Clin Oncol, 1996 Oct 01; 14(10). PMID: 8874335
Highly Cited.
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.
D R Budman, D A Berry, +8 authors, E Frei.
J Natl Cancer Inst, 1998 Aug 27; 90(16). PMID: 9719081
Highly Cited.
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
A D Thor, D A Berry, +9 authors, E T Liu.
J Natl Cancer Inst, 1998 Sep 25; 90(18). PMID: 9747866
[Treatment of breast cancer: from hormones to antibodies].
J Eucker, A Emde, K Possinger.
Internist (Berl), 2006 Oct 26; 47(12). PMID: 17063333
Review.
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Lisa K Dunnwald, Mary Anne Rossing, Christopher I Li.
Breast Cancer Res, 2007 Jan 24; 9(1). PMID: 17239243    Free PMC article.
Highly Cited.
Managing high-risk breast cancer.
Frances M Palmieri, Edith A Perez.
Semin Oncol Nurs, 2007 Feb 17; 23(1). PMID: 17303514    Free PMC article.
Review.
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.
Chee-Onn Leong, Nick Vidnovic, +2 authors, Leif W Ellisen.
J Clin Invest, 2007 Apr 21; 117(5). PMID: 17446929    Free PMC article.
Highly Cited.
Molecular profiling in breast cancer.
Shannon R Morris, Lisa A Carey.
Rev Endocr Metab Disord, 2007 Apr 28; 8(3). PMID: 17464566
Review.
Treatment of premenopausal women with early breast cancer: old challenges and new opportunities.
Stefan Aebi, Olivia Pagani.
Drugs, 2007 Jun 30; 67(10). PMID: 17600388
Review.
Using clinical trial data to tailor adjuvant treatments for individual patients.
Meredith M Regan, Richard D Gelber, International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).
Breast, 2007 Aug 28; 16 Suppl 2. PMID: 17719227    Free PMC article.
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer.
Alison K Conlin, Andrew D Seidman.
Mol Diagn Ther, 2007 Dec 15; 11(6). PMID: 18078353
Review.
Mithramycin analogues generated by combinatorial biosynthesis show improved bioactivity.
Irfan Baig, María Perez, +5 authors, Jürgen Rohr.
J Nat Prod, 2008 Jan 17; 71(2). PMID: 18197601    Free PMC article.
Building pathway clusters from Random Forests classification using class votes.
Herbert Pang, Hongyu Zhao.
BMC Bioinformatics, 2008 Feb 08; 9. PMID: 18254968    Free PMC article.
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
G G Kimmick, C Cirrincione, +9 authors, Cancer and Leukemia Group B.
Breast Cancer Res Treat, 2008 Feb 29; 113(3). PMID: 18306034    Free PMC article.
Update of evidence in chemotherapy for breast cancer.
Hiroyasu Yamashiro, Masakazu Toi.
Int J Clin Oncol, 2008 Mar 01; 13(1). PMID: 18307012
Review.
Systematic review of statistical methods used in molecular marker studies in cancer.
Andrew J Vickers, Kwang Jang, +2 authors, Michael W Kattan.
Cancer, 2008 Mar 06; 112(8). PMID: 18320601    Free PMC article.
Systematic Review.
Avoiding the use of anthracyclines in the adjuvant therapy of breast cancer: the "TC" (docetaxel and cyclophosphamide) regimen.
Kevin R Fox.
Curr Oncol Rep, 2008 Mar 28; 10(1). PMID: 18366954
The role of ovarian ablation in the adjuvant therapy of breast cancer.
Sing-Huang Tan, Antonio C Wolff.
Curr Oncol Rep, 2008 Mar 28; 10(1). PMID: 18366958
Review.
Minireview: nuclear receptors and breast cancer.
Suzanne D Conzen.
Mol Endocrinol, 2008 Apr 18; 22(10). PMID: 18417735    Free PMC article.
Review.
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.
Yasmine Nadler, Robert L Camp, +4 authors, Yuval Kluger.
Breast Cancer Res, 2008 Apr 24; 10(2). PMID: 18430249    Free PMC article.
The screening mammography paradox: better when found, perhaps better not to find.
D A Berry.
Br J Cancer, 2008 May 29; 98(11). PMID: 18506172    Free PMC article.
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Lori J Goldstein, Anne O'Neill, +4 authors, Nancy E Davidson.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678836    Free PMC article.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.
Juan de la Haba-Rodríguez, Emilio Alba, +8 authors, Enrique Aranda.
Clin Transl Oncol, 2008 Sep 18; 10(9). PMID: 18796372
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
James J Dignam, Vanja Dukic, +3 authors, Norman Wolmark.
Breast Cancer Res Treat, 2008 Oct 03; 116(3). PMID: 18830816    Free PMC article.
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Olivia Pagani, Shari Gelber, +14 authors, International Breast Cancer Study Group.
Breast Cancer Res Treat, 2008 Oct 28; 116(3). PMID: 18953651    Free PMC article.
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
A K Koutras, K T Kalogeras, +16 authors, Hellenic Cooperative Oncology Group (HeCOG).
Br J Cancer, 2008 Nov 06; 99(11). PMID: 18985033    Free PMC article.
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
Shaheenah Dawood, Kristine Broglio, +9 authors, Ana Maria Gonzalez-Angulo.
J Clin Oncol, 2008 Dec 03; 27(2). PMID: 19047281    Free PMC article.
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
Lorenzo Gianni, Shari Gelber, +9 authors, Aron Goldhirsch.
Eur J Cancer, 2008 Dec 09; 45(4). PMID: 19062268    Free PMC article.
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
Olivia Pagani, Karen N Price, +9 authors, International Breast Cancer Study Group (IBCSG).
Breast Cancer Res Treat, 2009 Jan 13; 117(2). PMID: 19137426    Free PMC article.
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Judith Hugh, John Hanson, +11 authors, Charles Vogel.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204205    Free PMC article.
Highly Cited.
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Jason A Zell, Walter Y Tsang, +2 authors, Hoda Anton-Culver.
Breast Cancer Res, 2009 Feb 21; 11(1). PMID: 19228416    Free PMC article.
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.
Sara López-Tarruella, Miguel Martín.
Breast Cancer Res, 2009 Apr 07; 11(2). PMID: 19344489    Free PMC article.
Review.
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Joseph A Sparano, Stacy Moulder, +16 authors, Said M Sebti.
Clin Cancer Res, 2009 Apr 09; 15(8). PMID: 19351752    Free PMC article.
Time-varying effects of prognostic factors associated with disease-free survival in breast cancer.
Loki Natarajan, Minya Pu, +9 authors, John P Pierce.
Am J Epidemiol, 2009 May 01; 169(12). PMID: 19403844    Free PMC article.
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Adjuvant chemotherapy in older women with early-stage breast cancer.
Hyman B Muss, Donald A Berry, +23 authors, CALGB Investigators.
N Engl J Med, 2009 May 15; 360(20). PMID: 19439741    Free PMC article.
Highly Cited.
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Xiang H-F Zhang, Qiongqing Wang, +5 authors, Joan Massagué.
Cancer Cell, 2009 Jul 04; 16(1). PMID: 19573813    Free PMC article.
Highly Cited.
The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.
Linbo Wang, Zhinong Jiang, +3 authors, Weimin Fan.
BMC Cancer, 2009 Jul 14; 9. PMID: 19591668    Free PMC article.
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.
Christine B Ambrosone, William E Barlow, +13 authors, Kathy S Albain.
J Clin Oncol, 2009 Sep 16; 27(30). PMID: 19752340    Free PMC article.
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.
Marcus C Tan, Fatema Al Mushawah, +4 authors, Julie A Margenthaler.
Am J Surg, 2009 Oct 06; 198(4). PMID: 19800460    Free PMC article.
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
Review.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Takahiro Nakayama, Shinzaburo Noguchi.
Oncologist, 2010 Jan 19; 15(1). PMID: 20080863    Free PMC article.
Review.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, +19 authors, Judy E Garber.
J Clin Oncol, 2010 Jan 27; 28(7). PMID: 20100965    Free PMC article.
Highly Cited.
Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.
Kazuaki Takabe, Roger H Kim, +7 authors, Sarah Spiegel.
J Biol Chem, 2010 Jan 30; 285(14). PMID: 20110355    Free PMC article.
Highly Cited.
Chemotherapy: dose-dense treatment for triple-negative breast cancer.
Eitan Amir, Alberto Ocana, +2 authors, Bostjan Seruga.
Nat Rev Clin Oncol, 2010 Feb 02; 7(2). PMID: 20118978
Triple-negative breast cancer: role of specific chemotherapy agents.
Steven J Isakoff.
Cancer J, 2010 Feb 19; 16(1). PMID: 20164691    Free PMC article.
Review.
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Marco Colleoni, Bernard F Cole, +9 authors, Barry A Gusterson.
J Clin Oncol, 2010 May 12; 28(18). PMID: 20458051    Free PMC article.
Current controversies in the management of breast cancer.
I Tusquets, L García-Estévez, +17 authors, A Lluch.
Clin Transl Oncol, 2010 May 14; 12(4). PMID: 20462837
Review.
Molecular basis for therapy resistance.
Per E Lønning.
Mol Oncol, 2010 May 15; 4(3). PMID: 20466604    Free PMC article.
Review.
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
Sherry X Yang, Joseph P Costantino, +7 authors, Sandra M Swain.
J Clin Oncol, 2010 May 19; 28(18). PMID: 20479407    Free PMC article.
Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key.
Stefan Ambs.
PLoS Med, 2010 Jun 04; 7(5). PMID: 20520798    Free PMC article.
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
Fiona M Blows, Kristy E Driver, +40 authors, David Huntsman.
PLoS Med, 2010 Jun 04; 7(5). PMID: 20520800    Free PMC article.
Highly Cited.
Genomic index of sensitivity to endocrine therapy for breast cancer.
W Fraser Symmans, Christos Hatzis, +13 authors, Lajos Pusztai.
J Clin Oncol, 2010 Aug 11; 28(27). PMID: 20697068    Free PMC article.
Highly Cited.
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
Y H Chia, M J Ellis, C X Ma.
Br J Cancer, 2010 Aug 12; 103(6). PMID: 20700118    Free PMC article.
Review.
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.
Daniel J Toft, Vincent L Cryns.
Mol Endocrinol, 2010 Sep 24; 25(2). PMID: 20861225    Free PMC article.
Review.
Triple-negative breast cancer: disease entity or title of convenience?
Lisa Carey, Eric Winer, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2010 Sep 30; 7(12). PMID: 20877296
Highly Cited. Review.
Breast cancer assessment tools and optimizing adjuvant therapy.
Catherine Oakman, Libero Santarpia, Angelo Di Leo.
Nat Rev Clin Oncol, 2010 Oct 27; 7(12). PMID: 20975745
Review.
Is Chemoendocrine Treatment without Alternative?
Richard Greil.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076602    Free PMC article.
Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.
Marc L Citron.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076605    Free PMC article.
Randomized adjuvant trials in oncology: a necessity or time-consuming luxury?
Joseph Ragaz.
Breast Cancer Res, 2011 Jan 05; 12 Suppl 4. PMID: 21172076    Free PMC article.
Are current development programs realising the full potential of new agents?
Per Eystein Lønning.
Breast Cancer Res, 2011 Jan 05; 12 Suppl 4. PMID: 21172086    Free PMC article.
Post-diagnosis dietary factors and survival after invasive breast cancer.
Jeannette M Beasley, Polly A Newcomb, +8 authors, Walter C Willett.
Breast Cancer Res Treat, 2011 Jan 05; 128(1). PMID: 21197569    Free PMC article.
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
P Karlsson, Z Sun, +14 authors, A Goldhirsch.
Ann Oncol, 2011 Feb 18; 22(10). PMID: 21325445    Free PMC article.
Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?
Philippe L Bedard, Fatima Cardoso.
Nat Rev Clin Oncol, 2011 Mar 03; 8(5). PMID: 21364525
Review.
Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach.
Kerri M Winters-Stone, Britta Torgrimson, +5 authors, Shiuh-Wen Luoh.
Arch Phys Med Rehabil, 2011 Mar 04; 92(4). PMID: 21367394    Free PMC article.
Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases.
Mohammad F El-Sibai, Cynthia Cohen, +2 authors, Momin T Siddiqui.
Int J Physiol Pathophysiol Pharmacol, 2009 Jan 01; 1(1). PMID: 21383878    Free PMC article.
ER-/ER+ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection.
Wei Ying, Sumeng Wang, Junfeng Shi, Yujie Sun.
Med Oncol, 2011 Mar 15; 29(2). PMID: 21399998
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
David L Rimm, Torsten O Nielsen, +18 authors, Cancer and Leukemia Group B Pathology Committee.
J Clin Oncol, 2011 Apr 27; 29(16). PMID: 21519016    Free PMC article.
Breast cancer adjuvant therapy: time to consider its time-dependent effects.
Ismail Jatoi, William F Anderson, Jong-Hyeon Jeong, Carol K Redmond.
J Clin Oncol, 2011 May 11; 29(17). PMID: 21555693    Free PMC article.
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Hervé Bonnefoi, Martine Piccart, +19 authors, EORTC 10994/BIG 1-00 Study Investigators.
Lancet Oncol, 2011 May 17; 12(6). PMID: 21570352    Free PMC article.
A preliminary study of the effectiveness of chinese therapeutic food on regulating female reproductive hormones.
Lulu Fu, Hong Xu.
Integr Med Insights, 2011 May 27; 6. PMID: 21614163    Free PMC article.
Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.
Gretchen Kimmick.
Curr Treat Options Oncol, 2011 Jun 04; 12(3). PMID: 21638199
Review.
Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
Alíz Nikolényi, Gabriella Uhercsák, +7 authors, Zsuzsanna Kahán.
Pathol Oncol Res, 2011 Jun 18; 18(1). PMID: 21681601
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
Donald A Berry, Naoto T Ueno, +21 authors, Taner Demirer.
J Clin Oncol, 2011 Jul 20; 29(24). PMID: 21768471    Free PMC article.
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
Arif H Kamal, Charles L Loprinzi, +7 authors, Matthew P Goetz.
Oncologist, 2011 Sep 22; 16(10). PMID: 21934103    Free PMC article.
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.
E Brain, C Levy, +12 authors, P Fumoleau.
Br J Cancer, 2011 Oct 20; 105(10). PMID: 22009030    Free PMC article.
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Jocelyne Jacquemier, Jean-Marie Boher, +12 authors, François Bertucci.
Breast Cancer Res, 2011 Nov 03; 13(6). PMID: 22044691    Free PMC article.
How do I treat "triple-negative" disease.
Christos Vaklavas, Andres Forero-Torres.
Curr Treat Options Oncol, 2011 Nov 04; 12(4). PMID: 22048876
Reporting of adjuvant breast cancer trials: when is the right time?
Helena M Earl.
J Clin Oncol, 2011 Nov 23; 30(1). PMID: 22105825    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Laura J Esserman, Donald A Berry, +32 authors, I-SPY 1 TRIAL Investigators.
Breast Cancer Res Treat, 2011 Dec 27; 132(3). PMID: 22198468    Free PMC article.
Highly Cited.
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer.
Dawn L Hershman, Elizabeth T Wilde, +4 authors, Alfred I Neugut.
J Clin Oncol, 2012 Feb 09; 30(8). PMID: 22312106    Free PMC article.
Triple-negative breast cancer: adjuvant therapeutic options.
Ayca Gucalp, Tiffany A Traina.
Chemother Res Pract, 2012 Feb 09; 2011. PMID: 22312556    Free PMC article.
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study.
P Pronzato, G Mustacchi, +4 authors, M E Cazzaniga.
Int J Breast Cancer, 2012 Feb 15; 2011. PMID: 22332011    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Review.
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.
H R Ali, S-J Dawson, +3 authors, C Caldas.
Br J Cancer, 2012 Apr 28; 106(11). PMID: 22538974    Free PMC article.
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Nancy U Lin, Ann Vanderplas, +7 authors, Jane C Weeks.
Cancer, 2012 May 01; 118(22). PMID: 22544643    Free PMC article.
Highly Cited.
The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
Zhinong Jiang, Junlan Guo, +3 authors, Linbo Wang.
J Exp Clin Cancer Res, 2012 May 05; 31. PMID: 22553917    Free PMC article.
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.
Per E Lønning.
Ther Adv Med Oncol, 2012 May 17; 4(3). PMID: 22590486    Free PMC article.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Bruno Coudert, Bernard Asselain, +18 authors, UNICANCER Breast Group.
Oncologist, 2012 May 23; 17(7). PMID: 22610153    Free PMC article.
Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
R L Aft, M Naughton, K Trinkaus, K Weilbaecher.
Br J Cancer, 2012 May 24; 107(1). PMID: 22617128    Free PMC article.
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Laura J Esserman, Donald A Berry, +25 authors, Nola Hylton.
J Clin Oncol, 2012 Jun 01; 30(26). PMID: 22649152    Free PMC article.
Highly Cited.
Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Min-Bin Chen, Ya-Qun Zhu, +4 authors, Pei-Hua Lu.
PLoS One, 2012 Jul 07; 7(6). PMID: 22768103    Free PMC article.
Personalized therapy for pancreatic cancer: Myth or reality in 2010?
Tzu-Chuan Jane Huang, Siddhartha Kar, Milind Javle.
J Gastrointest Oncol, 2010 Sep 01; 1(1). PMID: 22811802    Free PMC article.
A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.
Jessica E Pritchard, Patrick M Dillon, +2 authors, Sarah J Parsons.
Oncology, 2012 Sep 12; 83(6). PMID: 22964943    Free PMC article.
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
I Vaz-Luis, E P Winer, N U Lin.
Ann Oncol, 2012 Oct 02; 24(2). PMID: 23022997    Free PMC article.
Review.
Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer.
Keiichi Kontani, Noriyuki Kuroda, +11 authors, Hiroyasu Yokomise.
Cancer Biol Ther, 2012 Nov 02; 14(1). PMID: 23114645    Free PMC article.
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Allison W Kurian, Daphne Y Lichtensztajn, +8 authors, Scarlett L Gomez.
Breast Cancer Res Treat, 2012 Nov 10; 137(1). PMID: 23139057    Free PMC article.
A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
Adisorn Ratanaphan.
Int J Mol Sci, 2012 Dec 04; 13(11). PMID: 23203101    Free PMC article.
Review.
Treatment when prognostic factors do not match St. Gallen recommendations: profiling of prognostic factors among HR(+) and HER2(-) breast cancer patients.
Kyoko Satoh, Maki Tanaka, +2 authors, Tatsuyuki Kakuma.
World J Surg, 2012 Dec 12; 37(3). PMID: 23229849
The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer.
Chiara Lucchetti, Isabella Caligiuri, +2 authors, Flavio Rizzolio.
PLoS One, 2013 Feb 08; 8(2). PMID: 23390529    Free PMC article.
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.
Diana Crivellari, Kathryn P Gray, +16 authors, Aron Goldhirsch.
Breast, 2013 Mar 05; 22(2). PMID: 23453899    Free PMC article.
Systemic cancer therapy: achievements and challenges that lie ahead.
Michael O Palumbo, Petr Kavan, +8 authors, Gerald Batist.
Front Pharmacol, 2013 May 16; 4. PMID: 23675348    Free PMC article.
In vitro effects of herbicides and insecticides on human breast cells.
Jessica D Rich, Seth M Gabriel, Jennifer R Schultz-Norton.
ISRN Toxicol, 2012 Jan 01; 2012. PMID: 23762632    Free PMC article.
Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women.
Hsin-Shun Tseng, Che Lin, +5 authors, Dar-Ren Chen.
World J Surg Oncol, 2013 Jun 19; 11. PMID: 23768133    Free PMC article.
The p53-estrogen receptor loop in cancer.
C Berger, Y Qian, X Chen.
Curr Mol Med, 2013 Jul 20; 13(8). PMID: 23865427    Free PMC article.
Review.
Genes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers.
Xianxiao Zhou, Tongwei Shi, +6 authors, Zheng Guo.
PLoS One, 2013 Jul 23; 8(7). PMID: 23875016    Free PMC article.
A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character.
Mitsuhiro Hayashi, Yutaka Yamamoto, Noboru Takata, Hirotaka Iwase.
Springerplus, 2013 Jul 23; 2(1). PMID: 23875131    Free PMC article.
Competing risks analysis in mortality estimation for breast cancer patients from independent risk groups.
Shengfan Zhang, Julie S Ivy, +2 authors, Bonnie C Yankaskas.
Health Care Manag Sci, 2013 Nov 19; 17(3). PMID: 24242701
A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.
Julie R Palmer, Christine B Ambrosone, Andrew F Olshan.
Cancer Causes Control, 2013 Dec 18; 25(3). PMID: 24343304    Free PMC article.
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.
Priscilla Merriam, William M Sikov.
Breast Cancer (Dove Med Press), 2011 Jan 01; 3. PMID: 24367183    Free PMC article.
Review.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
J Baselga, A Manikhas, +11 authors, M Rozencweig.
Ann Oncol, 2014 Jan 10; 25(3). PMID: 24401928    Free PMC article.
The application of Oncotype DX in early-stage lymph-node-positive disease.
Sarika Jain, William J Gradishar.
Curr Oncol Rep, 2014 Jan 21; 16(1). PMID: 24442572
Review.
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Sara M Tolaney, Joon Jeong, +7 authors, Ian E Krop.
Cancer Med, 2014 Jan 28; 3(2). PMID: 24464780    Free PMC article.
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Debora de Melo Gagliato, Ana M Gonzalez-Angulo, +5 authors, Mariana Chavez-Macgregor.
J Clin Oncol, 2014 Jan 29; 32(8). PMID: 24470007    Free PMC article.
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.
Otávio Clark, Tobias Engel Ayer Botrel, Luciano Paladini, Mariana Bhering Andrade Ferreira.
Core Evid, 2014 Jan 31; 9. PMID: 24476748    Free PMC article.
Review.
Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index association.
Noorasmaliza Mdpaiman, Siti Aishah Md Ali, +7 authors, Srijit Das.
PLoS One, 2014 Mar 04; 9(2). PMID: 24586570    Free PMC article.
Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
Katsunori Tozuka, Jun Horiguchi, +7 authors, Izumi Takeyoshi.
Mol Clin Oncol, 2013 Jan 01; 1(1). PMID: 24649129    Free PMC article.
Estrogen signaling and the DNA damage response in hormone dependent breast cancers.
C Elizabeth Caldon.
Front Oncol, 2014 May 27; 4. PMID: 24860786    Free PMC article.
Review.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, +14 authors, Eric P Winer.
J Clin Oncol, 2014 Aug 06; 33(1). PMID: 25092775    Free PMC article.
Highly Cited.
Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114866    Free PMC article.
Review.
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.
Clara N Lee, Matthew H Wetschler, +4 authors, Karen R Sepucha.
BMC Med Inform Decis Mak, 2014 Aug 22; 14. PMID: 25142035    Free PMC article.
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.
Zorka Inic, Milan Zegarac, +6 authors, Snezana Jancic.
Clin Med Insights Oncol, 2014 Sep 25; 8. PMID: 25249766    Free PMC article.
Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.
Diego Munoz, Aimee M Near, +16 authors, Sylvia K Plevritis.
J Natl Cancer Inst, 2014 Sep 27; 106(11). PMID: 25255803    Free PMC article.
Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
Yu Ren, Dalliah M Black, +7 authors, Min Yi.
PLoS One, 2014 Oct 22; 9(10). PMID: 25333877    Free PMC article.
An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer.
Xin Zhou, Xiaping Wang, +3 authors, Ping Liu.
J Exp Clin Cancer Res, 2014 Nov 07; 33. PMID: 25373603    Free PMC article.
Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.
Tommaso Susini, Barbara Berti, +8 authors, Simonetta Bianchi.
Onco Targets Ther, 2014 Dec 09; 7. PMID: 25484594    Free PMC article.
The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
Rocío Montes de Oca, Zachary A Gurard-Levin, +12 authors, Geneviève Almouzni.
Mol Oncol, 2014 Dec 17; 9(3). PMID: 25497280    Free PMC article.
Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?
Debarshi Jana, Diptendra Kumar Sarkar, +3 authors, Syamsundar Mandal.
Indian J Surg Oncol, 2015 Mar 15; 5(4). PMID: 25767340    Free PMC article.
A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer.
Thomas G Frazier, Kevin R Fox, +13 authors, Michael S Broder.
Pharmaceuticals (Basel), 2015 Mar 20; 8(1). PMID: 25789420    Free PMC article.
Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.
Chi Zhang, Shuang Wang, +7 authors, Eileen P Connolly.
Springerplus, 2015 Aug 05; 4. PMID: 26240784    Free PMC article.
Breast cancer survival in African-American women by hormone receptor subtypes.
Tomi Akinyemiju, Justin Xavier Moore, Sean F Altekruse.
Breast Cancer Res Treat, 2015 Aug 08; 153(1). PMID: 26250393    Free PMC article.
Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
Eun Sook Ko, Heon Han, +5 authors, Seok Jin Nam.
Korean J Radiol, 2015 Sep 12; 16(5). PMID: 26357493    Free PMC article.
CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.
Lisa A Carey.
Clin Cancer Res, 2015 Sep 17; 21(18). PMID: 26374072    Free PMC article.
Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem.
Fotinos-Ioannis D Dimitrakopoulos, Anastasia Kottorou, +2 authors, Haralabos P Kalofonos.
J Breast Cancer, 2015 Oct 17; 18(3). PMID: 26472970    Free PMC article.
Review.
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes.
Yehoda M Martei, Jennifer M Matro.
Breast Cancer (Dove Med Press), 2015 Oct 28; 7. PMID: 26504408    Free PMC article.
Review.
Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.
Ismail Jatoi, Hanna Bandos, +4 authors, Norman Wolmark.
J Natl Cancer Inst, 2015 Nov 01; 108(1). PMID: 26518884    Free PMC article.
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
Mariana Chavez-MacGregor, Christina A Clarke, Daphne Y Lichtensztajn, Sharon H Giordano.
JAMA Oncol, 2015 Dec 15; 2(3). PMID: 26659132    Free PMC article.
Highly Cited.
Efficacy of chemotherapy after hormone therapy for hormone receptor-positive metastatic breast cancer.
Ryutaro Mori, Yasuko Nagao.
SAGE Open Med, 2014 Jan 01; 2. PMID: 26770749    Free PMC article.
Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.
Walter M Gregory, Christopher J Twelves, +4 authors, David A Cameron.
Breast Cancer Res Treat, 2016 Jan 20; 155(2). PMID: 26783036    Free PMC article.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Ashley M Brinkman, Guojun Chen, +5 authors, Wei Xu.
Biomaterials, 2016 Jun 09; 101. PMID: 27267625    Free PMC article.
Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods.
Junjie Li, Yirong Liu, Yizhou Jiang, Zhimin Shao.
PLoS One, 2016 Jun 15; 11(6). PMID: 27299729    Free PMC article.
Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast.
Quyen D Chu, Prakash Peddi.
Clin Med Insights Oncol, 2016 Jul 12; 10. PMID: 27398043    Free PMC article.
Challenges of treating incidental synchronous bilateral breast cancer with differing tumour biology.
Jonathan Walter Esclovon, Melissa Ponder, Nail Aydin, Subhasis Misra.
BMJ Case Rep, 2016 Aug 20; 2016. PMID: 27539136    Free PMC article.
Operation with less adjuvant therapy for elderly breast cancer.
Akimitsu Yamada, Kazutaka Narui, +5 authors, Itaru Endo.
J Surg Res, 2016 Aug 28; 204(2). PMID: 27565077    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Review.
Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Yoon Yang Jung, Chang Lim Hyun, +5 authors, Han Suk Ryu.
J Breast Cancer, 2016 Oct 11; 19(3). PMID: 27721875    Free PMC article.
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT.
Zhen-Yu He, San-Gang Wu, +4 authors, Yong Bao.
Transl Oncol, 2016 Nov 27; 10(1). PMID: 27888707    Free PMC article.
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
Joachim Diessner, Manfred Wischnewsky, +8 authors, Achim Wöckel.
PLoS One, 2016 Dec 20; 11(12). PMID: 27992550    Free PMC article.
Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.
Carmel Jacobs, Mark Clemons, +8 authors, John Hilton.
Support Care Cancer, 2017 Jan 28; 25(6). PMID: 28127659
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study.
Xiaosong Chen, Guolin Ye, +2 authors, Kunwei Shen.
Chin J Cancer Res, 2017 Feb 09; 28(6). PMID: 28174484    Free PMC article.
TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.
Rainer Fagerholm, Sofia Khan, +50 authors, Heli Nevanlinna.
Oncotarget, 2017 Feb 10; 8(11). PMID: 28179588    Free PMC article.
Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up.
Xu Liu, Ling-Long Tang, +7 authors, Jun Ma.
J Cancer, 2017 Mar 07; 8(3). PMID: 28261347    Free PMC article.
Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer.
Münire Kayahan, Ufuk Oğuz İdiz, +3 authors, Mahmut Müslümanoğlu.
J Breast Health, 2014 Jan 01; 10(4). PMID: 28331672    Free PMC article.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Bernhard C Pestalozzi, Christoph Tausch, +17 authors, Swiss Group for Clinical Cancer Research (SAKK).
BMC Cancer, 2017 Apr 15; 17(1). PMID: 28407750    Free PMC article.
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Jorge Gómez-Miragaya, Marta Palafox, +19 authors, Eva González-Suárez.
Stem Cell Reports, 2017 May 02; 8(5). PMID: 28457887    Free PMC article.
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Neelima Vidula, Christina Yau, +2 authors, Hope S Rugo.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577080    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Sentiment Analysis of an Online Breast Cancer Support Group: Communicating about Tamoxifen.
Mark L Cabling, Jeanine W Turner, +4 authors, Vanessa B Sheppard.
Health Commun, 2017 Jul 06; 33(9). PMID: 28678549    Free PMC article.
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
Minetta C Liu, Brandelyn N Pitcher, +20 authors, William T Barry.
NPJ Breast Cancer, 2016 Jan 01; 2. PMID: 28691057    Free PMC article.
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel.
Chengcheng Gong, Zhongyi Yang, +9 authors, Yingjian Zhang.
Sci Rep, 2017 Jul 28; 7(1). PMID: 28747642    Free PMC article.
Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer.
Marzia A Locatelli, Giuseppe Curigliano, Alexandru Eniu.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785182    Free PMC article.
Review.
New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
Oreste Claudio Buonomo, Emanuele Caredda, +6 authors, Paolo Orsaria.
PLoS One, 2017 Sep 19; 12(9). PMID: 28922402    Free PMC article.
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.
Daniel E Carvajal-Hausdorf, Nikita Mani, +2 authors, David L Rimm.
J Immunother Cancer, 2017 Oct 19; 5(1). PMID: 29037255    Free PMC article.
A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.
Qiao Li, Zhao Yang, +8 authors, Pin Zhang.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100275    Free PMC article.
Immunotherapy in triple-negative breast cancer.
Heather Katz, Mohamed Alsharedi.
Med Oncol, 2017 Dec 20; 35(1). PMID: 29255938
Review.
Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge.
Yehoda M Martei, Lydia E Pace, Jane E Brock, Lawrence N Shulman.
Clin Lab Med, 2018 Feb 08; 38(1). PMID: 29412880    Free PMC article.
Review.
Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis.
Qiao-Hui Zhan, Jian-Qin Fu, +2 authors, Chuan Wang.
Oncotarget, 2018 Feb 09; 9(2). PMID: 29416807    Free PMC article.
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Xiujuan Wu, Peng Tang, +6 authors, Yi Zhang.
Nat Commun, 2018 Feb 28; 9(1). PMID: 29483583    Free PMC article.
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Alexey A Larionov.
Front Oncol, 2018 Apr 20; 8. PMID: 29670855    Free PMC article.
Review.
Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women.
Govind Babu, A Goel, +8 authors, Purvish M Parikh.
South Asian J Cancer, 2018 May 04; 7(2). PMID: 29721478    Free PMC article.
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.
Ji Hyun Park, Jin-Hee Ahn, Sung-Bae Kim.
ESMO Open, 2018 May 17; 3(Suppl 1). PMID: 29765774    Free PMC article.
Review.
G-protein receptor kinases 2, 5 and 6 redundantly modulate Smoothened-GATA transcriptional crosstalk in fetal mouse hearts.
Antonietta Franco, Lihong Zhang, +2 authors, Gerald W Dorn.
J Mol Cell Cardiol, 2018 Jul 04; 121. PMID: 29969579    Free PMC article.
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
John Hilton, Carol Stober, +4 authors, Mark Clemons.
PLoS One, 2018 Jul 25; 13(7). PMID: 30040817    Free PMC article.
Overview of Breast Cancer Therapy.
Tracy-Ann Moo, Rachel Sanford, Chau Dang, Monica Morrow.
PET Clin, 2018 Aug 14; 13(3). PMID: 30100074    Free PMC article.
Review.
Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX.
Theodore Vougiouklakis, Vassiliki Saloura, +4 authors, Yo Matsuo.
Oncotarget, 2018 Aug 31; 9(61). PMID: 30159125    Free PMC article.
Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.
Nan Wu, Jinghua Zhang, +5 authors, Juntian Liu.
Oncol Lett, 2018 Sep 27; 16(4). PMID: 30250564    Free PMC article.
Review.
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Saranya Chumsri, Zhuo Li, +9 authors, E Aubrey Thompson.
J Clin Oncol, 2019 Oct 18; 37(35). PMID: 31622131    Free PMC article.
Indications for prognostic gene expression profiling in early breast cancer.
Erin F Cobain, Daniel F Hayes.
Curr Treat Options Oncol, 2015 May 02; 16(5). PMID: 25929335
Review.
Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Daniel Herr, Manfred Wischnewsky, +10 authors, Achim Wöckel.
PLoS One, 2019 Jul 10; 14(7). PMID: 31283775    Free PMC article.
Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis.
Yunhai Li, Dejuan Yang, +4 authors, Guosheng Ren.
Aging (Albany NY), 2019 Aug 26; 11(16). PMID: 31446432    Free PMC article.
Review.
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Ge Qin, Xin Wang, +18 authors, Wuguo Deng.
Nat Commun, 2020 Apr 05; 11(1). PMID: 32245950    Free PMC article.
Exploring refinements in targeted behavioral medicine intervention to advance public health.
Abby C King, David F Ahn, Audie A Atienza, Helena C Kraemer.
Ann Behav Med, 2008 Jun 24; 35(3). PMID: 18568380    Free PMC article.
Incorporating biomarkers to improve statistical power of immunotherapeutic neoadjuvant clinical trials in patients with triple-negative breast cancer.
Feng Gao, Guoqiao Wang, +3 authors, Chengjie Xiong.
Stat Biopharm Res, 2019 Aug 31; 11(3). PMID: 31467642    Free PMC article.
Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients.
Lifen Cai, Yiwei Tong, +3 authors, Xiaosong Chen.
Sci Rep, 2020 Apr 29; 10(1). PMID: 32341397    Free PMC article.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Review.
Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Sumadi Lukman Anwar, Widya Surya Avanti, +5 authors, Wahyu Wulaningsih.
World J Surg Oncol, 2020 Jun 01; 18(1). PMID: 32473643    Free PMC article.
Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis.
Julie Labrosse, Marie Osdoit, +4 authors, Enora Laas.
PLoS One, 2020 Jun 06; 15(6). PMID: 32502222    Free PMC article.
Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.
Ling-Cheng Wang, Ling-Sheng Wang, +6 authors, De-Qiang Zhu.
Technol Cancer Res Treat, 2020 Jun 09; 19. PMID: 32508292    Free PMC article.
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Anna-Karin Tzikas, Szilard Nemes, Barbro K Linderholm.
Breast Cancer Res Treat, 2020 Jun 12; 182(3). PMID: 32524352    Free PMC article.
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.
Jenny Furlanetto, Sibylle Loibl.
Breast Care (Basel), 2020 Aug 11; 15(3). PMID: 32774215    Free PMC article.
Review.
The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.
Masanori Oshi, Hideo Takahashi, +6 authors, Kazuaki Takabe.
Cells, 2020 Jul 12; 9(7). PMID: 32650578    Free PMC article.
Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer.
Shen Li, Yan Xu, +5 authors, Xiangyu Ma.
NPJ Precis Oncol, 2020 Sep 15; 4. PMID: 32923685    Free PMC article.
Virtual screening of novel compounds as potential ER-alpha inhibitors.
Jakkanaboina TilakVijay, Kandimalla Vivek Babu, Addepally Uma.
Bioinformation, 2019 Jun 30; 15(5). PMID: 31249434    Free PMC article.
RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway.
Guanglei Chen, Lisha Sun, +3 authors, Weiguang Liu.
Am J Cancer Res, 2019 Sep 10; 9(8). PMID: 31497344    Free PMC article.
Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
Diego F Munoz, Sylvia K Plevritis.
Med Decis Making, 2018 Mar 20; 38(1_suppl). PMID: 29554464    Free PMC article.
A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.
Diego F Munoz, Cong Xu, Sylvia K Plevritis.
Med Decis Making, 2018 Mar 20; 38(1_suppl). PMID: 29554473    Free PMC article.
Change of paradigm in treating elderly with breast cancer: are we undertreating elderly patients?
Chwanrow Karim Baban, Liam Devane, James Geraghty.
Ir J Med Sci, 2018 Jun 24; 188(2). PMID: 29934872
Review.
Nuclear Receptors Are Differentially Expressed and Activated in KAIMRC1 Compared to MCF7 and MDA-MB231 Breast Cancer Cells.
Atef Nehdi, Rizwan Ali, +9 authors, Mohamed Boudjelal.
Molecules, 2019 May 31; 24(11). PMID: 31141879    Free PMC article.
High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer.
Masanori Oshi, Fernando A Angarita, +4 authors, Kazuaki Takabe.
Cancers (Basel), 2020 Dec 30; 12(12). PMID: 33371179    Free PMC article.
The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Abdulmohsen Alkushi, Ahmad Omair, +5 authors, Omalkhair Abulkhair.
Cureus, 2021 Mar 20; 13(2). PMID: 33738150    Free PMC article.
Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer.
Wenting Ni, Hui Fan, +8 authors, Yin Lu.
Front Oncol, 2021 May 11; 11. PMID: 33968724    Free PMC article.
Prognostic Outcomes of Signet Ring Cell Carcinoma of the Breast.
Maahum Mehdi, Amanda L Kong, +3 authors, Chandler S Cortina.
J Surg Res, 2021 Apr 07; 264. PMID: 33823490    Free PMC article.
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.
Fabio Puglisi, Lorenzo Gerratana, +18 authors, Lucia Del Mastro.
NPJ Breast Cancer, 2021 Jun 30; 7(1). PMID: 34183674    Free PMC article.